Top in ID: FDA approval of Rezzayo; symptoms from latent TB therapy
The FDA recently approved Rezzayo, a weekly injectable treatment for adults with candidemia and invasive candidiasis.
“The FDA approval of Rezzayo is tremendous news for those of us who have been hoping for a new option to treat our patients with these deadly fungal infections,” Infectious Disease News Editorial Board Member George R. Thompson, MD, a professor of clinical medicine at the University of California, Davis School of Medicine, and principal investigator in the ReSTORE phase 3 trial of the drug, said in a press release.
It was the top story in infectious disease last week.
Another top story was about a study that found patients receiving once-weekly rifapentine plus isoniazid reported mostly mild symptoms from the therapy, which resolved without stopping treatment. Researchers reported that nearly half of patients experiencing systemic drug reactions completed therapy regardless of their symptoms.
Read these and more top stories in infectious disease below:
FDA approves new treatment for candidemia, invasive candidiasis
The FDA approved rezafungin for injection to treat candidemia and invasive candidiasis in adults, offering a new treatment for people with limited or no other options. Read more.
Patients with latent TB receiving 3HP report symptoms resolved without stopping treatment
Most patients with latent tuberculosis receiving a once-weekly combination of rifapentine and isoniazid reported symptoms from the therapy that resolved without stopping treatment, researchers found. Read more.
Pneumococcal vaccination: A public health priority
Over the past several years, adult pneumococcal vaccine recommendations have evolved based on the development of new vaccines. Read more.
Most HIV mortality now due to non-AIDS-related comorbidities
Because people with HIV who are being successfully treated with ART have a close to normal life expectancy, most deaths among those with HIV are now caused by unrelated comorbidities, a study found. Read more.
Hooked on ID with Monica V. Mahoney, PharmD, BCPS, BCIDP, FCCP, FIDSA, FIDP
My journey in infectious diseases started out with an intense hatred and utter confusion. Read more.